Fukuda Denshi Announces the U.S. Launch of the HN-100 Neuromuscular Transmission (NMT) Monitoring Module

Fukuda Denshi launches the HN-100 NMT Module in the U.S., delivering precise EMG-based monitoring to enhance patient safety and anesthesia care.

REDMOND, WA, UNITED STATES, October 10, 2025 /EINPresswire.com/ -- Fukuda Denshi USA, Inc. is proud to announce the U.S. launch of the HN-100 Neuromuscular Transmission (NMT) Monitoring Module, a new solution designed to deliver accurate, quantitative neuromuscular blockade monitoring for anesthesia care in the operating room (OR) and intensive care unit (ICU).

Built on advanced surface electromyography (EMG) technology, the HN-100 enables clinicians to measure compound muscle action potential (CMAP) and quantify the depth of neuromuscular blockade – including deep levels – with exceptional precision. This innovation empowers more individualized anesthesia management and supports safer, more efficient patient care.
The HN-100 leverages EMG technology from Senzime’s TetraGraph^® system through a collaboration with Senzime AB, further enhancing the clinical capabilities of Fukuda Denshi’s monitoring solutions.

The HN-100 seamlessly integrates with Fukuda Denshi’s DS-1200 patient monitoring system, allowing facilities to enhance their monitoring capabilities without changing existing workflows. It offers multiple stimulation modes, including Train-of-Four (TOF), Post-Tetanic Count (PTC), and Single Twitch (ST), and features automated stimulation settings for ease of use and optimized performance.

---

Advancing Patient Safety with Precision Monitoring
By enabling continuous, real-time monitoring of neuromuscular function, the HN-100 helps clinicians optimize neuromuscular blocking agent dosing, ensure adequate reversal prior to extubation, and reduce the risk of residual blockade.
Through this collaboration, Fukuda Denshi combines its expertise in patient monitoring with Senzime’s proven EMG technology to deliver a next-generation solution for anesthesia care.
Its ability to assess even deep levels of paralysis provides anesthesia teams with valuable insights for safer perioperative management.

The module’s compact design and simple integration with existing DS-1200 monitors make it a practical and efficient solution for a wide range of clinical settings, including operating rooms and intensive care units.

"The launch of the HN-100 underscores Fukuda Denshi's commitment to helping hospitals improve patient outcomes while simplifying the clinician's experience,” said Justin Criddle, Vice President of Sales at Fukuda Denshi USA, Inc. “By delivering practical, integrated solutions that enhance safety, efficiency and value, we are supporting providers and achieving lasting impact for both patients and their organizations."

---

Availability
The HN-100 Neuromuscular Transmission (NMT) Monitoring Module is now available in the United States as part of Fukuda Denshi’s DS-1200 patient monitoring system.

---

About Fukuda Denshi
Fukuda Denshi is a global leader in patient monitoring and diagnostic solutions, dedicated to advancing medical technology and improving patient care. With decades of experience in clinical innovation, Fukuda Denshi delivers solutions that help healthcare professionals monitor, diagnose, and treat patients with confidence. Learn more at www.fukudaamerica.com.

---

**For more information:**
www.fukudaamerica.com
CustomerService@fukudaamerica.com

Customer Service
Fukuda Denshi USA, Inc.
+1 800-365-6668
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.